文献速递淋巴瘤

来那度胺联合CHOP治疗血管免疫母细胞性T细胞淋巴瘤的2期试验整合分析

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

该多中心2期试验在60至80岁初治血管免疫母细胞性T细胞淋巴瘤(AITL)患者中评估来那度胺联合CHOP方案,主要终点为治疗结束时完全代谢缓解(CMR)率。78例可评估患者中CMR率为41%(95%CI 30%-52.7%),低于预设的55%成功率阈值。整合分析揭示了TET2、RHOA、DNMT3A和IDH2等复发性突变的临床影响。

要点

  • 来那度胺联合CHOP未提高AITL患者的CMR率,研究未达预设成功阈值。
  • 2年无进展生存率为42.1%,2年总生存率为59.2%。
  • IDH2突变与独特病理临床特征相关,DNMT3A突变与更短PFS相关。

核心结论

  • 来那度胺联合CHOP未能改善AITL患者的完全代谢缓解率。
  • 该试验阐明了AITL中复发性突变的临床影响。

研究设计与样本

  • 多中心2期试验,纳入80例既往未经治疗的60至80岁AITL患者,78例纳入疗效和安全性分析。
  • 来那度胺25 mg每日口服,每周期用14天,联合8周期CHOP21方案。
  • 主要终点为治疗结束时完全代谢缓解(CMR)率。

主要发现

  • CMR率为41%(95%CI 30%-52.7%),低于预设的55%成功率阈值。
  • 2年无进展生存率为42.1%(95%CI 30.9%-52.8%),2年总生存率为59.2%(95%CI 47.3%-69.3%)。
  • 最常见毒性为血液学毒性,导致15%患者终止治疗。
  • TET2、RHOA、DNMT3A和IDH2突变分别见于78%、54%、32%和22%的患者。
  • IDH2突变与独特病理和临床特征相关,DNMT3A突变与更短PFS相关。

临床怎么用

  • 来那度胺联合CHOP不应作为AITL的常规治疗选择,因未达预设CMR成功率。
  • IDH2和DNMT3A突变状态可能有助于AITL的风险分层和临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy. Lenalidomide, which has been safely combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60 to 80 years. The primary objective was the complete metabolic response (CMR) rate at the end of treatment. Seventy-eight of the 80 patients enrolled were included in the efficacy and safety analysis. CMR was achieved in 32 (41%; 95% confidence interval [CI], 30%-52.7%) patients, which was below the prespecified CMR rate of 55% defined as success in the study. The 2-year progression-free survival (PFS) was 42.1% (95% CI, 30.9%-52.8%), and the 2-year overall survival was 59.2% (95% CI, 47.3%-69.3%). The most common toxicities were hematologic and led to treatment discontinuation in 15% of patients. This large prospective and uniform series of AITL treatment data was used to perform an integrative analysis of clinical, pathologic, biologic, and molecular data. TET2, RHOA, DNMT3A, and IDH2 mutations were present in 78%, 54%, 32%, and 22% of patients, respectively. IDH2 mutations were associated with distinct pathologic and clinical features and DNMT3A was associated with shorter PFS. In conclusion, the combination of lenalidomide and CHOP did not improve the CMR in AITL patients. This trial clarified the clinical impact of recurrent mutations in AITL. This trial was registered at www.clincialtrials.gov as #NCT01553786.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021. PMID: 33496747. doi:10.1182/bloodadvances.2020003081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。